GoAI
Get started
Actinium Pharmaceuticals, Inc. logo

Actinium Pharmaceuticals, Inc.

ATNM

AMEXHealthcareBiotechnology

Open in GoAI

Previous close

$1.10

−$0.02 · -1.79%

Aug 21, 4:00 PM ET

ATNM company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Sell

Trim exposure — unfavorable risk-reward

Valuation

63

Undervalued

Momentum

18

Strong Down

Sentiment

38

Bearish

Risk resilience

34

High Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Industry
Biotechnology
Sector
Healthcare
Headquarters
US

Market position

Day range

Current $1.10

52-week range

Current $1.10

Open
$1.11
Previous close
$1.12
Volume
142.88K
Market cap
34.51M USD
50-day average
$0.9383
+17.24% above average
200-day average
$1.1752
-6.40% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
-3.88M USD
P/E (TTM)
3.06×
P/B (TTM)
1.14×
P/S (TTM)
0.98×
EV / EBITDA
0.12×
Earnings yield
-79.87%
Free cash flow yield
-58.18%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
101.13%
Operating margin
27.23%
Net margin
32.23%
Return on equity
-432.56%
Return on assets
-65.45%
Return on invested capital
-81.40%

Financial health

Debt / equity
0.04×
Current ratio
6.2×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends6520%-19160%-44839%-70519%Gross margin, FY2021: 54.20%Gross margin, FY2022: 100.00%Gross margin, FY2023: 100.00%Gross margin, FY2025: 100.00%Operating margin, FY2021: -2182.17%Operating margin, FY2022: -3311.07%Operating margin, FY2023: -64098.77%Operating margin, FY2025: -40274.44%Net margin, FY2021: -2165.56%Net margin, FY2022: -3205.53%Net margin, FY2023: -60269.14%Net margin, FY2025: -37652.22%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 54.20%. Gross margin FY2022 100.00%. Gross margin FY2023 100.00%. Gross margin FY2025 100.00%. Operating margin FY2021 -2182.17%. Operating margin FY2022 -3311.07%. Operating margin FY2023 -64098.77%. Operating margin FY2025 -40274.44%. Net margin FY2021 -2165.56%. Net margin FY2022 -3205.53%. Net margin FY2023 -60269.14%. Net margin FY2025 -37652.22%.

Income trends

Revenue

90K USD+11.11%

Operating income

−36.25M USD+13.95%

Net income

−33.89M USD+11.39%
Income trends across reported periods6.45M USD−14.78M USD−36M USD−57.23M USDRevenue, FY2021: 1.14M USDRevenue, FY2022: 1.03M USDRevenue, FY2023: 81K USDRevenue, FY2025: 90K USDOperating income, FY2021: −24.96M USDOperating income, FY2022: −34.1M USDOperating income, FY2023: −51.92M USDOperating income, FY2024: −42.12M USDOperating income, FY2025: −36.25M USDNet income, FY2021: −24.77M USDNet income, FY2022: −33.02M USDNet income, FY2023: −48.82M USDNet income, FY2024: −38.24M USDNet income, FY2025: −33.89M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 1.14M USD. Revenue FY2022 1.03M USD. Revenue FY2023 81K USD. Revenue FY2025 90K USD. Operating income FY2021 −24.96M USD. Operating income FY2022 −34.1M USD. Operating income FY2023 −51.92M USD. Operating income FY2024 −42.12M USD. Operating income FY2025 −36.25M USD. Net income FY2021 −24.77M USD. Net income FY2022 −33.02M USD. Net income FY2023 −48.82M USD. Net income FY2024 −38.24M USD. Net income FY2025 −33.89M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue90K USD—81K USD1.03M USD1.14M USD
Cost of goods sold—811K USD——524K USD
Gross profit90K USD−811K USD81K USD1.03M USD620K USD
Research and development21.12M USD30.05M USD38.67M USD23.14M USD17.51M USD
Selling, general, and administrative15.21M USD12.08M USD13.33M USD12M USD8.08M USD
Operating expenses36.34M USD41.31M USD52M USD35.13M USD25.58M USD
Interest income2.36M USD3.88M USD3.1M USD1.09M USD190K USD
Depreciation and amortization821K USD811K USD790K USD699K USD524K USD
Operating income−36.25M USD−42.12M USD−51.92M USD−34.1M USD−24.96M USD
Net income−33.89M USD−38.24M USD−48.82M USD−33.02M USD−24.77M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
64%
7 beats, 3 misses, 1 met estimate
Average EPS surprise
+10.09%
11 comparable reports
Latest EPS result
0.89
Estimate 0.89 · Met by 0.00%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates10.46-0.08-0.62Q1 '25BeatQ2 '25MissQ3 '25BeatQ4 '25BeatQ1 '26MissQ2 '26BeatQ3 '26MetQ4 '26Estimate
Q1 2025, reported Mar 31, 2025: actual -0.21, estimate -0.37, surprise +43.24%, Beat. Q2 2025, reported May 9, 2025: actual -0.51, estimate -0.26, surprise -96.15%, Miss. Q3 2025, reported Aug 8, 2025: actual -0.22, estimate -0.32, surprise +31.25%, Beat. Q4 2025, reported Nov 14, 2025: actual -0.16, estimate -0.25, surprise +36.00%, Beat. Q1 2026, reported Mar 30, 2026: actual -0.19, estimate -0.187, surprise -1.78%, Miss. Q2 2026, reported May 8, 2026: actual -0.18, estimate -0.22, surprise +18.18%, Beat. Q3 2026, reported Aug 7, 2026: actual 0.89, estimate 0.89, surprise 0.00%, Met estimate. Q4 2026, reported Nov 13, 2026: actual —, estimate -0.27, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates37.79M25.22M12.64M57.38KQ1 '24No estimateQ1 '25No estimateQ4 '25BeatQ1 '26EstimateQ2 '26EstimateQ3 '26MetQ4 '26Estimate
Q1 2024, reported Mar 29, 2024: actual 81K USD, estimate —, surprise —, Comparison unavailable. Q1 2025, reported Mar 31, 2025: actual 810K USD, estimate —, surprise —, Comparison unavailable. Q4 2025, reported Nov 14, 2025: actual 90K USD, estimate 67.5K USD, surprise +33.33%, Beat. Q1 2026, reported Mar 30, 2026: actual —, estimate 600K USD, surprise —, Comparison unavailable. Q2 2026, reported May 8, 2026: actual —, estimate 2.5M USD, surprise —, Comparison unavailable. Q3 2026, reported Aug 7, 2026: actual 35M USD, estimate 35M USD, surprise 0.00%, Met estimate. Q4 2026, reported Nov 13, 2026: actual —, estimate 1.25M USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$11.07

906.36% upside
Past 12 months12-month forecastHigh $24.26Average $11.07Low $4.00

Rating distribution

11 ratings
Strong buy00%
Buy11100%
Hold00%
Sell00%
Strong sell00%

Recent analyst actions

5 institutions

ATNM news

prnewswire.com

Actinium Pharmaceuticals Announces Actimab-A Intellectual Property and Manufacturing Advances and Provides NYSE American Listing Update

NEW YORK, Aug. 14, 2026 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today announced advances across its…

Read source
defenseworld.net

Lakewood-Amedex Biotherapeutics (NASDAQ:LABT) vs. Actinium Pharmaceuticals (NYSE:ATNM) Financial Contrast

Actinium Pharmaceuticals (NYSE: ATNM - Get Free Report) and Lakewood-Amedex Biotherapeutics (NASDAQ: LABT - Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the…

Read source
defenseworld.net

Palatin Technologies (OTCMKTS:PTNT) and Actinium Pharmaceuticals (NYSE:ATNM) Head to Head Review

Actinium Pharmaceuticals (NYSE: ATNM - Get Free Report) and Palatin Technologies (OTCMKTS:PTNT - Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare the two…

Read source
prnewswire.com

Actinium Presents New ATNM-400 Data in KRAS and EGFR Mutant Models at SNMMI 2026 Supporting a Mutation-Agnostic Opportunity In Non-Small Cell Lung Cancer

New KRAS-mutant data show ATNM-400 outperformed standard-of-care inhibitors sotorasib and adagrasib as a monotherapy. Treatment with these agents increased expression of the ATNM-400 target greater than 3.5x and enhanced…

Read source
prnewswire.com

Actinium Pharmaceuticals Oral Presentation at SNMMI 2026 Highlights ATNM-400 Overcoming Resistance to All Three Approved Androgen Receptor Inhibitors and Offers Flexible, Well-Tolerated Dosing in Prostate Cancer Models

New data demonstrated ATNM-400 remains potently active in prostate cancer cells and tumors resistant to all three approved androgen receptor inhibitors (ARPIs) -enzalutamide (Xtandi®), apalutamide (Erleada®), and…

Read source
prnewswire.com

Actinium Appoints Accomplished Oncology Expert Steffen Heeger MD, MSc as Chief Medical Officer to Drive Rejuvenated Pipeline Development

Proven Chief Medical Officer at several publicly listed and clinical-stage oncology companies with successful track record developing multiple modalities including radiotherapies from preclinical through global approvals…

Read source

Corporate actions

Corporate action history

Stock split

Effective Aug 11, 2020

1:30

ETFs holding ATNM

Funds reporting this stock among their holdings, ordered by reported position size.

Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
768.74K
Weight
0.00%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$378.24+0.44%
Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
263.93K
Weight
0.00%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%
iShares Micro-Cap ETF logoiShares Micro-Cap ETFIWC
Market value
121.1K
Weight
0.01%
AUM
1.53B USD
Expense ratio
0.60%
Price / 1D
$198.39+1.10%

Continue in GoAI

Research ATNM

research.disclaimer